Regulators, payers, and prescribers: can we fill the gaps

Original Text

Francesco Pignatti a, Xavier Luria a, Eric Abadie b, Hans-Georg Eichler a

The approval of new cancer drugs in Europe is built on the benefit—risk paradigm, based on objective criteria of efficacy and safety, to the exclusion of economic considerations. This limits the extent to which the European Medicines Agency (EMA) can contribute to the debate on cost-effectiveness. Still, EU regulators share the growing concerns about sustainability of expenditure on cancer drugs. Regulators are exposed to challenges from stakeholders who often have opposing views, such as the

 

 

The Lancet Oncology, Volume 12, Issue 10, Pages 930 - 931, September 2011

<Previous Article|Next Article>

doi:10.1016/S1470-2045(11)70229-7Cite or Link Using DOI

...